Reddy's Labs Receives DCGI Approval for Zytorvi in Cancer Treatment

Dr. Reddy's has obtained approval from India's Drugs Controller General (DCGI) for Zytorvi, a drug intended for use in cancer treatment. The clearance allows the company to market the product in India for the specified oncology indication. Regulatory approval of this kind follows the review of the drug's safety and efficacy data by the national regulator. The development adds to the company's oncology portfolio in the Indian market.